Cyclontane and sodium oxybate pharmaceutical composition for desynchronosis

What does this source report?

The combination was investigated for activity rhythms, performance, operant learning and EEG sleep. REM duration exceeded the untreated desynchronosis group, but REM latency remained prolonged relative to baseline: recovery was incomplete.

Population and setting

Rodent circadian-disruption experiments; 18-hour light/dark schedule

Evidence type

Patent / reported experiments

Preparation

See the original report; formulation details require verification.

Source language

Russian

Title provenance

Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.

What are the limitations?

• Combination findings cannot establish Cyclontane’s independent effect; patent evidence does not establish human efficacy or safety.
• No clinical sleep benefit or safe self-use regimen follows from these experiments.

Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.

Document format: Patent

Review depth: Selected methods and sleep-result passages reviewed

Source access and review scope

Selected source passages checked; complete methods and risk of bias not appraised.

Recorded source-check date: 2026-10-03. This date does not imply a completed systematic review.

Open original source or index record ↗

Cite and trace this record

Original source: Author unconfirmed. Cyclontane and sodium oxybate pharmaceutical composition for desynchronosis RU2674342C2; filed 28 November 2016; Russian Federation represented by Ministry of Defense 2018.

Molekul research summary: https://molekul.io/research/adk-cyclontane-2018-patent. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.

Related compound profiles